Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • Wednesday
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerGlobeNewsWire • 10/23/26
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/21/26
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026GlobeNewsWire • 10/19/26
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence TestGlobeNewsWire • 10/16/26
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to RadiationGlobeNewsWire • 09/29/26
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026GlobeNewsWire • 09/25/26
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?Zacks Investment Research • 09/25/26
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing PlatformGlobeNewsWire • 09/14/26
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry WoesZacks Investment Research • 09/09/26
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire • 09/01/26
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?Zacks Investment Research • 08/25/26
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a TurnaroundZacks Investment Research • 08/17/26
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to DeclineZacks Investment Research • 07/23/26